H
Henry Masur
Researcher at National Institutes of Health
Publications - 414
Citations - 56261
Henry Masur is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Pneumocystis carinii & Pneumonia. The author has an hindex of 105, co-authored 402 publications receiving 52273 citations. Previous affiliations of Henry Masur include Burroughs Wellcome Fund & Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics.
Lynn Rozenberg,Bart L. Haagmans,Avidan U. Neumann,Grace Chen,Mary McLaughlin,Rachel S. Levy-Drummer,Henry Masur,Robin L. Dewar,Peter Ferenci,Marcelo Silva,Maria S Viola,Michael A. Polis,Shyam Kottilil +12 more
TL;DR: The pharmacodynamic parameter EC50, estimated from nonlinear fitting of the viral kinetics together with peg-IFN2b concentration data, showed that HIV/ hepatitis C virus co-infected African-Americans have lower sensitivity to interferon-alpha thus giving rise to slower viral decline.
Journal ArticleDOI
Proteome-Wide Anti-Hepatitis C Virus (HCV) and Anti-HIV Antibody Profiling for Predicting and Monitoring the Response to HCV Therapy in HIV-Coinfected Patients
Peter D. Burbelo,Joseph A. Kovacs,Kathryn H. Ching,Alexandra T. Issa,Michael J. Iadarola,Alison A. Murphy,Joerg F. Schlaak,Henry Masur,Michael A. Polis,Shyam Kottilil +9 more
TL;DR: Analysis of pre- and posttreatment samples revealed significant decreases in the combined anti-core, anti-E1, and anti-NS4 HCV antibody titers in those with SVRs but not in those who experienced relapse or who did not respond.
Journal ArticleDOI
A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).
Eleanor Wilson,Emily Covert,Jennifer Hoffmann,Emily Comstock,Benjamin Emmanuel,Lydia Tang,Jennifer Husson,Joel Chua,Angie Price,Poonam Mathur,Elana Rosenthal,Sarah Kattakuzhy,Henry Masur,Shyam Kottilil +13 more
TL;DR: Twelve weeks of SOF/VEL/VOX was safe and effective in patients with relapsed HCV after initial combination oral Hepatitis C therapy and treatment response was not diminished with HIV-infection or previous poor adherence or noncompletion of DAA-based therapy.
Journal ArticleDOI
A Multiple Drug Interaction Study of Stavudine with Agents for Opportunistic Infections in Human Immunodeficiency Virus-Infected Patients
Stephen C. Piscitelli,Grace Kelly,Robert E. Walker,Joseph A. Kovacs,Judith Falloon,Richard T. Davey,Sangita Raje,Henry Masur,Michael A. Polis +8 more
TL;DR: Although the maximum concentration of drug in serum was significantly decreased when the drug was given in combination with three opportunistic infection medications, the area under the concentration-time curve did not significantly differ across various treatment regimens.
Journal ArticleDOI
Does Pneumocystis carinii prophylaxis still need to be lifelong
Henry Masur,Jonathan E. Kaplan +1 more
TL;DR: The implementation of prophylaxis to prevent an initial episode of pneumonia or a subsequent episode (secondary prophYLaxis) was the first intervention that substantially increased survival and improved the quality of life for patients with HIV infection.